Amycretin: Novo's Amylin and GLP-1 Co-Agonist
Amycretin explained: Novo Nordisk's single-molecule amylin and GLP-1 agonist in oral and injectable trials. Not medical advice.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
Amycretin is an investigational Novo Nordisk molecule that activates both amylin and GLP-1 receptors in one compound — unlike CagriSema, which combines two separate drugs. Early trials tested both a weekly injection and a daily oral form, reporting sizeable weight loss over short treatment periods with gastrointestinal side effects. It is not approved. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
What users report here
Anonymous accounts are collected on the Cagrilintide reports. They are personal stories, often with other compounds in the mix, not evidence of effect.
Related topics
related peptides:
community guides:
More confessions from the archive
Community Q&A
- Is amycretin the same as CagriSema?
- No. CagriSema combines cagrilintide and semaglutide; amycretin is one molecule acting on both receptor types.
- Is amycretin approved?
- No. It is in clinical development.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.